Join us in-person in Chicago, IL at AACR Annual Meeting 2025.
Our Posters
Mice Humanized for the Immune System as Validated Tool for Therapeutic Antibody Development
Date and Time: Friday, 28 April, 9:00am- 12:00pm
Location: Poster Section 3
Presenter: Sophie Chabot, Group Leader In vivo pharmacology and clinical translation
Therapeutic antibodies modulating the immune response are frequently specific for human proteins but fail to cross-react with the corresponding rodent homologs. Hence, their preclinical development requires suitable “humanized” mouse models, i.e. mice bearing a human immune system, so that immunotherapies can be evaluated in a more relevant immune context in vivo. Such “humanized” mice are developed by reconstituting the immune system of immunodeficient animals with human immune cells from 2 possible origins: CD34+ hematopoietic stem cells (huCD34+ mice) isolated from cord blood, or mature peripheral blood mononuclear cells prepared from buffy coats.
A Novel CD2-Targeted Costimulatory Bispecific Antibody Platform for Enhancing CD3 T Cell Engager-Based Cancer Immunotherapy
Date and Time: Monday, 28 April, 2025, 2:00pm - 5:00pm
Presenter: Gerhard Niederfellner, Senior Vice President Innovate Oncology
CD3-based T cell engagers (TCEs) are a clinically successful class of bispecific antibodies that has delivered 11 approved agents to date, albeit primarily for treatment of blood cancers. These agents provide a strong signal 1 for redirecting polyclonal T cells, regardless of their native specificity, to kill cancer cells. However, when only receiving signal 1 for prolonged periods of time without a costimulatory signal, T cells become anergic and exhausted. In part due to the lack of costimulatory signals in the tumor microenvironment, TCEs have had limited therapeutic success in solid tumor indications so far. Interestingly, single cell RNA sequencing data from multiple solid tumor types revealed that a high percentage of tumor infiltrating T cells express high levels of CD2 but not CD28 or other costimulatory receptors.
